Biotech Values

[ghmm]

OCRX:

What do you dislike about the 2B design is it that both arms get SOC? The dose is 2x the investigator sponsored trials which surprised me a bit. I was disappointed with the slow enrollment they said its picked up a bit (I think they may have loosened some enrollment criteria but by memory don't recall what)

I am long the stock (though not one of my bigger positions).